Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Apr 10;22(8):3923.
doi: 10.3390/ijms22083923.

Mitochondrial Dysfunction and Chronic Inflammation in Polycystic Ovary Syndrome

Affiliations
Review

Mitochondrial Dysfunction and Chronic Inflammation in Polycystic Ovary Syndrome

Siarhei A Dabravolski et al. Int J Mol Sci. .

Abstract

Polycystic ovarian syndrome (PCOS) is the most common endocrine-metabolic disorder affecting a vast population worldwide; it is linked with anovulation, mitochondrial dysfunctions and hormonal disbalance. Mutations in mtDNA have been identified in PCOS patients and likely play an important role in PCOS aetiology and pathogenesis; however, their causative role in PCOS development requires further investigation. As a low-grade chronic inflammation disease, PCOS patients have permanently elevated levels of inflammatory markers (TNF-α, CRP, IL-6, IL-8, IL-18). In this review, we summarise recent data regarding the role of mtDNA mutations and mitochondrial malfunctions in PCOS pathogenesis. Furthermore, we discuss recent papers dedicated to the identification of novel biomarkers for early PCOS diagnosis. Finally, traditional and new mitochondria-targeted treatments are discussed. This review intends to emphasise the key role of oxidative stress and chronic inflammation in PCOS pathogenesis; however, the exact molecular mechanism is mostly unknown and requires further investigation.

Keywords: chronic inflammation; insulin resistance; mitochondrial mutations; oxidative stress; polycystic ovarian syndrome.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Simplified map of the human mitochondrial genome. The mtDNA mutations associated with PCOS, listed in Table 1, are marked.

References

    1. Burt Solorzano C.M., McCartney C.R. Polycystic Ovary Syndrome. Endocrinol. Metab. Clin. N. Am. 2021;50:25–42. doi: 10.1016/j.ecl.2020.10.003. - DOI - PMC - PubMed
    1. NICHD About Polycystic Ovary Syndrome (PCOS) [(accessed on 20 February 2021)];2021 Available online: https://www.nichd.nih.gov/health/topics/pcos/conditioninfo.
    1. Yumiceba V., López-Cortés A., Pérez-Villa A., Yumiseba I., Guerrero S., García-Cárdenas J.M., Armendáriz-Castillo I., Guevara-Ramírez P., Leone P.E., Zambrano A.K., et al. Oncology and Pharmacogenomics Insights in Polycystic Ovary Syndrome: An Integrative Analysis. Front. Endocrinol. 2020;11:585130. doi: 10.3389/fendo.2020.585130. - DOI - PMC - PubMed
    1. Combs J.C., Hill M.J., Decherney A.H. Polycystic Ovarian Syndrome Genetics and Epigenetics. Clin. Obstet. Gynecol. 2021;64:20–25. doi: 10.1097/GRF.0000000000000581. - DOI - PMC - PubMed
    1. Mukherjee S. Pathomechanisms of Polycystic Ovary Syndrome Multidimensional Approaches. Front. Biosci. 2018;10:384–422. doi: 10.2741/e829. - DOI - PubMed

Substances